AXQ Capital’s Novo Nordisk NVO Stock Holding History

AXQ Capital’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,400	Closed	-$565K	–	641
2024 Q1	$565K	Sell	4,400 -14,600	-77%	-$1.74M	0.14%	275
2023 Q4	$1.97M	Buy	19,000 +10,500	+124%	+$1.04M	0.52%	19
2023 Q3	$773K	Buy	+8,500	New	+$749K	0.27%	133

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

AXQ Capital's NVO Position: Q2 2024 in Review

AXQ Capital sold out of Novo Nordisk (NVO) in Q2 2024, closing a stake of 4,400 shares — an estimated $565K sold.

AXQ Capital first reported a position in NVO in Q3 2023 and held it in 3 quarters. The position peaked at $1.97M in Q4 2023. 1,860 funds tracked by Wall St. Rank hold NVO as of Q2 2024.

AXQ Capital reported no remaining Novo Nordisk position as of Q2 2024 after selling out during the quarter.
AXQ Capital sold 4,400 Novo Nordisk shares in Q2 2024, an estimated $565K.
AXQ Capital first reported a position in Novo Nordisk in Q3 2023 and held it in 3 quarters.
AXQ Capital's Novo Nordisk position peaked at $1.97M in Q4 2023.
1,860 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2024.

Based on AXQ Capital's 13F filing for Q2 2024, filed 13 Aug 2024.